MedTrace Logo

Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy

NCT04727034 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1800

Last updated 2022-10-12

No results posted yet for this study

Summary

Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high. Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.

Conditions

Interventions

DRUG

Remimazolam tosylate

Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.

DRUG

Propofol

Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.

Sponsors & Collaborators

  • Shanghai East Hospital

    collaborator OTHER

  • Affiliated Hospital of Jiaxing University

    collaborator OTHER

  • The Second Affifiliated Hospital of Jiaxing University

    collaborator UNKNOWN

  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER

  • RenJi Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-02
Primary Completion
2023-07-01
Completion
2023-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04727034 on ClinicalTrials.gov